Boehringer Ingelheim Korea to market Parkinson's drug

Published: 2004-08-02 06:55:00

Updated: 2004-08-02 06:55:00

Following the merger between Pfizer and Pharmacia, Boehringer Ingelheim Korea is soon expected to exclusively market Mirapex (pramipexole dihydrochloride), which can be used to treat patients who have idiopathic Parkinson's disease in early and advanced states of the disease.

The company said that Mirapexrug was jointly developed by Upjohn and Boehringer Ingelheim.

Mirapex belongs to a cl...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.